Material Event Form 8 K

Item 8.01 Other Events

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals, Inc. (the "Company") announces compelling preclinical results demonstrating the ability of its licensed molecule, Telomir-1, to reverse insulin resistance to near pre-diabetes levels in a zebrafish model of Type 2 diabetes mellitus.

In collaboration with Pentagrit, the study evaluated Telomir-1 in oral formulations across three dosing regimens. Results showed a dose-dependent normalization of blood glucose levels, improved oral glucose tolerance, and significantly reduced Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values. HOMA-IR is a key measure of insulin sensitivity and resistance, with lower values indicating improved glucose regulation.

Key findings include:

●	Reversal of Insulin Resistance: Telomir-1 restored glucose homeostasis, reducing insulin resistance to near pre-diabetes levels.
●	Improved Glucose Metabolism: Enhanced results in Oral Glucose Tolerance Tests (OGTT) highlighted better glucose clearance.
●	Increased Survival Rates: Treated models showed improved survival, reinforcing Telomir-1's therapeutic potential.

A Novel Mechanism of Action

Telomir-1's novel mechanism of action targets iron metabolism, a known contributor to oxidative stress, beta-cell damage, and insulin resistance. By normalizing iron homeostasis, Telomir-1 addresses the root causes of Type 2 diabetes, offering a potential breakthrough in diabetes treatment.

These findings highlight Telomir-1's potential to transform the management of Type 2 diabetes by targeting underlying disease mechanisms and improving insulin sensitivity.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "plans," "anticipate," "believe," "estimate," "continue" and similar words. Such statements are only predictions and actual events or results may differ materially from those anticipated in these forward-looking statements. You should not place undue reliance on any forward-looking statements. In this report, such forward-looking statements relate to the anticipated benefits to the Company of the preclinical study results disclosed herein, the future of the Company's development and testing of Telomir-1, and other forward-looking matters related to the Company's plans as described herein. Readers are cautioned that actual future results related to these matters may deviate materially and adversely from the forward-looking statements contained herein. The Company does not assume any obligation to update forward-looking statements as circumstances change, except as required by securities laws.

Public link

Please use the above public link if you want to share this noodl on another website.